• The content of N-terminal brain natriuretic peptide and exercise tolerance in children with secondary cardiomyopathy and correction of the change agents by the «Ahvantar»
To content

The content of N-terminal brain natriuretic peptide and exercise tolerance in children with secondary cardiomyopathy and correction of the change agents by the «Ahvantar»

SOVREMENNAYA PEDIATRIYA. 2015.2(66):62-66; doi 10.15574/SP.2015.65.62

 

The content of N-terminal brain natriuretic peptide and exercise tolerance in children with secondary cardiomyopathy and correction of the change agents by the «Ahvantar»

 

Marushko U. V., Hischak T. V., Khomych O. V.

A.A. Bogomolets National Medical University, Kiev, Ukraine

 

Ame. To assess the level of NT-proBNP school-age children with secondary cardiomyopathy (SKMP) and its changes in the treatment of drug «Ahvantar».

 

Materials and methods. The study involved 53 children of the 9–17 years (30 children with SKMP and 23 healthy). A general clinical examination, echocardiography, Ruf'ye's test, bicycle stress test, determination of NT-proBNP in serum (ELISA). 

 

Results. The serum level of NT-proBNP in children with SKMP was within 51.78±11.02 fmol/ml, in 4.2 times more than the values in healthy children (12.68±3.05 fmol/ml) and correlated with the bulk properties of the heart — LVED (r=+0.52), LVES (r=+0.62), EF (r=-0.35), PWTd (r=+0.56), LVM (r=+0.51), and data stress test — PWC170 (r=+0.70), MOC170 (r=+0.61), CR (r=-0.33), IR (r=-0.46). Use of the drug «Ahvantar» led to improved myocardial oxygen supply and use of myocardium reserves. The level of NT-proVNP decreased by 2 times. Only 46.7% of children NT-proBNP at the end of the month of admission «Ahvantar» exceeding 27.88 fmol/ml.

 

Conclusions. The determination of NT-proBNP in children with SKMP along with carrying out bicycle stress test allows to characterize the adaptive capacity of the heart and promptly allocate risk group on the formation of heart failure; the drug L-carnitine «Ahvantar» for 1 month provides an opportunity to improve exercise tolerance and myocardium reserves, and normalize NT-proBNP content in blood serum in 55.3% children with SKMP.

 

Key words: school-age children, secondary cardiomyopathy, NT-proBNP, drugs L-carnitine.

 

REFERENCES

 

1. Голухова ЕЗ, Алиева АМ. 2007. Клиническое значение определения натрийуретических пептидов у больных с хронической сердечной недостаточностью. Кардиол и сердеч-сосуд хирург. 47;1: 45—51.

2. Марушко ЮВ, Гищак ТВ. 2014. Проблема діагностики і корекції зниженої толерантності до фізичного навантаження у дітей шкільного віку. Совр педиатрия. 7(63): 12—16.

3. Нагорная НВ, Пшеничная ЕВ, Бордюгова ЕВ. 2011. Клиническое значение показателя мозгового натрийуретического пептида у пациентов с хронической сердечной недостаточностью. Здоровье ребенка. 2: 115—120.

4. Орлова НВ, Михайлова ОВ, Захарова ТВ. 2011.Применение L-карнитина в комплексном лечении вегетососудистой дистонии гипотензивного типа у детей и подростков. Вопр совр педиатрии. 10;2: 11—15.

5. Саидова ВТ. 2013. Диагностическое значение натрийуретических пептидов в педиатрии. Казанский мед журн. 94;3: 350—354.

6. Солдатов ОМ, Ивянский ЛА, Ферапонтова ОВ. 2010. Обоснование использования L-карнитина в спортивной медицине. Рос вестн перинатол и педиатрии. 5: 90—97.

7. Балыкова ЛА, Ивянский СА, Урзяева АН и др. 2013. Элькар в детской спортивной практике. Рос вестн перинатол и педиатрии. 5: 45—48.

8. Benedictis F, Colaneri M, Osimani P et al. 2009. Aminoterminal Pro-B-type natriuretic peptide in refractory Kawasaki disease. Pediatr Cardiol. 6: 837—839. http://dx.doi.org/10.1007/s00246-009-9416-3; PMid:19365663

9. Bernus A, Wagner B, Accurso F et al. 2009.Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest. 135;3: 745—751. http://dx.doi.org/10.1378/chest.08-0187; PMid:18849405 PMCid:PMC2715554

10. Price J, Price A, Thomas K et al. 2006. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfun ction. Circulation. 114;10: 1063—1069. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.608869; PMid:16940194

11. Buddhe S, Dhuper S, Kim R et al. 2012. NT-proBNP levels improve the ability of predicting a hemodynamically significant patent ductus arteriosus in very low-birth-weight infants. J Clin Neonatol. 1;2: 82—86. http://dx.doi.org/10.4103/2249-4847.96758; PMid:24027696 PMCid:PMC3743145

12. Rusconi P, Ludwig D, Sandhu S et al. 2011. Cross validation of NT-proBNP as a predictor of cardiac transplant in children with dilated cardiomyopathy. J Amer Coll Cardiol. 14: 425—428. http://dx.doi.org/10.1016/S0735-1097(11)60425-7

13. Elsharawy S, Hassan B, Morsy S, Khalifa N. 2012. Diagnostic value of N-terminal probrain natriuretic peptide levels in pediatric patients with ventricular septal defect. The Egyptian Heart Journal. 64: 241—246. http://dx.doi.org/10.1016/j.ehj.2012.08.003

14. Eerola A, Jokinen E, Boldt T. 2006. The influence of percutaneous closure of patent ductus arteriosus on left ventricular size and function. J Am Coll Cardiol. 47: 1060—1066. http://dx.doi.org/10.1016/j.jacc.2005.09.067; PMid:16516094

15. Guidelines for the diagnosis and treatment of chronic heart failure. Task force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Eur Heart J. 2001. 22;17: 1527—1560.

16. Iwanaga Y, Miyazaki S. 2010. Heart failure, chronic kidney disease and biomarkers — an integrated viewpoint. Circ J. 74(7): 1274—1282. http://dx.doi.org/10.1253/circj.CJ-10-0444; PMid:20558890

17. Januzzi JL. 2006. Natriuretic peptide testing: a window into the diagnosis and prognosis of heart failure. Cleveland Clin J Med. 73: 149—157. http://dx.doi.org/10.3949/ccjm.73.2.149; PMid:16478039

18. Lammers A, Hislop A, Haworth S. 2009. Prognostic value of B_type natriuretic peptide in children with pulmonary hypertension. Int J Cardiol. 135;1: 21—26. http://dx.doi.org/10.1016/j.ijcard.2008.03.009; PMid:18599134

19. Lechner E, Wiesinger-Eidenberger G, Wagner O. 2009. Amino terminal pro B-type natriuretic peptide levels are elevated in the cord blood of neonates with congenital heart defect. Pediatr Res. 66: 466—469. http://dx.doi.org/10.1203/PDR.0b013e3181b3aee4; PMid:19581836

20. Lipshultz S, Miller T, Scully R. 2012. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 30: 1042—1049. http://dx.doi.org/10.1200/JCO.2010.30.3404; PMid:22370326 PMCid:PMC3341148

21. Nir A, Nasser N. 2005. Clinical value of NT_ProBNP and BNP in pediatric cardiology. J Cardiac Failure. 5: 76—80. http://dx.doi.org/10.1016/j.cardfail.2005.04.009

22. Nasser N, Perles Z, Rein AJ, Nir A. 2006. NT-proBNP as a marker for persistent cardiac disease in children with history of dilated cardiomyopathy and myocarditis. Pediatr Cardiol. 27: 87—90. http://dx.doi.org/10.1007/s00246-005-1027-z; PMid:16132296

23. Knecht K, Alexander M, Swearingen C et al. 2012. NTproBNP as a marker of rejection in pediatric heart transplant recipients. Pediatr Transplant. 16;4: 335—339. http://dx.doi.org/10.1111/j.1399-3046.2012.01659.x; PMid:22429516

24. Sagarad SV, Thakur B, Reddy SS et al. 2013. NT-proBNP in Myocarditis after Scorpion Sting Envenomation. Journal of Clinical and Diagnostic Research. 7(1): 118—121. http://dx.doi.org/10.7860/jcdr/2012/4858.2684

25. Nir A, Lindinger A, Rauh M et al. 2009. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. B Pediatr Cardiol. 30: 3-8. http://dx.doi.org/10.1007/s00246-008-9258-4; PMid:18600369

26. Brito D, Matias JS, Sargento L et al. 2004. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy. Rev Port Cardiol. 23: 1557—1582. PMid:15732658

27. Kaneko K, Yoshimura K, Ohashi A et al. 2011. Prediction of the risk of coronary arterial lesions in Kawasaki disease by brain natriuretic peptide. Pediatr Cardiol. 8: 1106—1109. http://dx.doi.org/10.1007/s00246-011-9986-8; PMid:21487793

28. Rauh M, Koch A. 2003. Plasma N-terminal Pro-B-type natriuretic peptide concentrations in a control population of infants and children. Clin Chem. 49: 1563—1564. http://dx.doi.org/10.1373/49.9.1563

29. Tabata T, Oki T, Yamada H et al. 2000. Relationship between left atrial appendage function and plasma concentration of atrial natriuretic peptide. Eur J Echocardiogr. 1;2: 130—137.

30. Yaris N, Ceviz N, Coskun T et al. 2002. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity. J Exl Clin Cancer Res. 21(2): 165—170. PMid:12148572

31. Sezgin EM, Ucar B, Kilic Z, Colak O. 2010. The value of serum N-terminal pro-brain natriuretic peptide levels in the differential diagnosis and follow-up of congestive cardiac failure and respiratory distress due to pulmonary aetiologies in infants and children. Cardiol Young. 20;5: 495—504. http://dx.doi.org/10.1017/S1047951110000533

32. Soker M, Kervancioglu M. 2005. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J. 26(8). 1197—1202. PMid:16127512

33. Hunt PJ, Yandle TG, Nicholls MG et al. 1995. The aminoterminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun. 214: 1175—1183.

34. Zaphiriou A, Robb S, Murray-Thomas T et al. 2005. The diagnostic accuracy of plasma BNP and N-pro BNP in patients referred from primary care with suspected heart failure: Results of the UK natriuretic peptide study. Eur J Heart Failure. 7: 537—541. http://dx.doi.org/10.1016/j.ejheart.2005.01.022; PMid:15921792

35. Vijlbrief D, Benders M, Kemperman H et al. 2012. Use of cardiac biomarkers in neonatology. Pediatr Res. 72: 337—343. http://dx.doi.org/10.1038/pr.2012.88; PMid:22797141

36. Shah A, Feraco A, Harmon C, Tacy T. 2009. Usefulness of various plasma biomarkers for diagnosis of heart failure in children with single ventricle physiology. Am J Cardiol. 104: 1280—1284. http://dx.doi.org/10.1016/j.amjcard.2009.06.046; PMid:19840577 PMCid:PMC2791782

37. Welisch E, Kleesiek K, Haas N. 2009. Aminoterminal ProBtype natriuretic peptide (NT-proBNP) levels for monitoring interventions in pediatric cardiac patients with stenotic lesions. Intern J Pediatr. 1: 6—12.